Castle Biosciences (CSTL) Current Assets (2018 - 2026)

Castle Biosciences has disclosed Current Assets across 9 years of filings, most recently posting $328.9 million for Q1 2026.

• Current Assets for Q1 2026 came in at $328.9 million, down 5.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $328.9 million (down 5.86% YoY), and the FY2025 annual result was $361.1 million, changed 0.26% from the prior year.
• Current Assets came in at $328.9 million for Q1 2026 at Castle Biosciences, down from $361.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $361.1 million in Q4 2025 to a low of $269.1 million in Q2 2023.
• The 5-year median for Current Assets is $320.4 million (2024), against an average of $318.5 million.
• Across the five-year window, Current Assets decreased 23.15% in 2022 and climbed 23.3% in 2024, its largest moves.
• Castle Biosciences' Current Assets stood at $292.3 million in 2022, then grew by 1.15% to $295.6 million in 2023, then increased by 21.82% to $360.2 million in 2024, then gained by 0.26% to $361.1 million in 2025, then dropped by 8.92% to $328.9 million in 2026.
• The last three Current Assets figures came in at $328.9 million (Q1 2026), $361.1 million (Q4 2025), and $357.6 million (Q3 2025), per Business Quant data.